Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gilead Sciences is conducting a Phase 2 study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-1427 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC). The study aims to assess the efficacy of GS-1427 in achieving a clinical response in participants with moderate to severe ulcerative colitis by Week 12, compared to a placebo.
The intervention being tested is GS-1427, an oral drug designed to treat ulcerative colitis. The study involves different doses of GS-1427 and a placebo for comparison.
The study design is interventional, with a randomized, sequential intervention model. It employs double masking, meaning both participants and investigators are unaware of the treatment allocations, and its primary purpose is treatment.
The study began on March 27, 2024, with a primary completion date set for Week 12. The estimated overall completion is projected for Week 76, with the last update submitted on July 15, 2025.
This update could influence Gilead Sciences’ stock performance by potentially boosting investor confidence if the results are favorable. The study’s progress may also impact the competitive landscape in the ulcerative colitis treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.